Back to top
more

Allogene Therapeutics (ALLO)

(Delayed Data from NSDQ)

$2.72 USD

2.72
2,534,770

+0.17 (6.46%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.73 +0.01 (0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag

by Zacks Equity Research

Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.

PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up

by Zacks Equity Research

PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.

Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag

by Zacks Equity Research

Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

by Zacks Equity Research

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up

by Zacks Equity Research

Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.

ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why

by Zacks Equity Research

ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.

FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing

by Zacks Equity Research

FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.

Corvus Pharma (CRVS) Stock Surges 69.2% in a Week: Here's Why

by Zacks Equity Research

Shares of Corvus Pharma (CRVS) surge 69% this week after the company provided updates on its pipeline development in the first quarter of 2023 earnings release.

Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View

by Zacks Equity Research

Jazz (JAZZ) reports dismal first-quarter results as earnings and sales miss expectations. The company reaffirms its financial guidance for 2023.

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

by Zacks Equity Research

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

by Zacks Equity Research

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

Iovance (IOVA) Posts Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

Novavax (NVAX) Q1 Earnings Lag, Stock Up 28% on Upbeat '23 View

by Zacks Equity Research

Novavax (NVAX) reports dismal Q1 earnings results, as earnings and revenues miss estimates. However, shares rise on the back of encouraging 2023 guidance and cost-reduction initiatives.

Wall Street Analysts Think Allogene Therapeutics (ALLO) Could Surge 184.59%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at an 184.6% upside potential for Allogene Therapeutics (ALLO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Esperion (ESPR) Q1 Earnings Miss Estimates, Sales Beat, Stock Up

by Zacks Equity Research

Esperion (ESPR) reports mixed first-quarter 2023 results, wherein earnings miss and revenues beat estimates. The stock of the company surges 5% on Tuesday. The company maintains 2023 guidance.

Acadia Pharmaceuticals (ACAD) Q1 Earnings & Sales Miss Estimates

by Zacks Equity Research

Acadia Pharmaceuticals (ACAD) reports weaker-than-expected first-quarter 2023 results as its earnings and revenues miss the Zacks Consensus Estimate. Management maintains its guidance for 2023.

Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.

CRISPR Therapeutics (CRSP) Q1 Earnings and Revenues Beat

by Zacks Equity Research

CRISPR Therapeutics (CRSP) provides updates for its gene therapy candidates.

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Allogene Therapeutics (ALLO) and 89BIO (ETNB) have performed compared to their sector so far this year.

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update

by Zacks Equity Research

Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.

Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance

by Zacks Equity Research

Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.